West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. 10-Q filed Jul 23, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 23, 2026: 27 added · 5 removed · 26 modified; 16 with only figures updated
-
Modified · Macroeconomic Factors
Beginning in 2025, the U.S. government imposed additional tariffs and trade restrictions on certain goods produced outside of the United States
. In response to these actions, and certain jurisdictions in which we operate have imposed or are considering imposing tariffs and restrictions on certain goods produced in the United States. In February 2026, the U.S. Supreme Court issued a ruling that certain tariffs imposed under the International Emergency Economics Power Act (“IEEPA”) were unauthorized. During the second quarter of 2026, the Company began applying for and receiving certain refunds for tariffs previously collected under the IEEPA. We continue to monitor this dynamicsituation to assesstrade-policy environment, including the potential impact ofthese tariffs on our business and actions we can take to minimize their impactexisting or future tariffs, trade restrictions, retaliatory measures, available refund processes and mitigation actions. Based ontheinformationavailable at this timecurrently available, we do notbelieve the impact will beexpect these matters to have a materialtoimpact on our 2026 results.
57 more changes in this Item, word by word, in Powerpack.
Powerpack